mRNA printers kick-start personalized medicines for all - Cormac_Sheridan
South Africa is setting up mRNA manufacture with new technologies that will ensure vaccines and therapeutics can be made locally and cheaply. Cape Town–based Afrigen joined forces with Belgian firms Univercells and eTheRNA. And the US-based Greenlight Biosciences is about to start a clinical trial of an mRNA vaccine in South Africa, to test a vaccine that will cost about $1 per dose—a fraction of the price of other mRNA vaccines.
Yet mRNA manufacturing has not kept pace with innovation—companies often rely on “antiquated approaches,” Singhvi says, as they have neither the time nor the resources to invest in better alternatives. At best, they are adding incremental improvements to out-of-date processes, and “that’s never going to move the needle.” Resilience has raised over $2 billion in equity financing and has big ambitions to put biomanufacturing on a similar footing to semiconductor manufacturing.
Dan Gibson, chief technology officer at Codex DNA, argues that this is already a reality in research settings. While he was at Synthetic Genomics, Gibson and colleagues, including J. Craig Venter, developed an automatedto produce nucleic acids and proteins directly from DNA sequence information. Codex DNA was later spun out to commercialize the technology.
To be fit for the clinic, mRNA molecules generated in this fashion will need regulatory blessing. Upcoming discussions with the US Food and Drug Administration about the company’s first investigational new drug filing, for NTX-0250, an RNA therapeutic targeting herpes simplex virus–driven cancers, will therefore have an important bearing on the technology’s immediate future.
Key to the Africa-wide initiative is a highly automated, low-cost manufacturing platform, which Charleroi, Belgium–based Univercells has developed with the help of funding from the Bill and Melinda Gates Foundation. Its cell-free production platform involves capital expenditure and running costs that are a fraction of those needed for current approaches.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Associate or Senior Editor, Nature BiotechnologyWe're seeking a talented immunologist to join us as an Associate or Senior Editor. The deadline for applications is August 29, 2022
Baca lebih lajut »
Next steps for the xenotransplantation of pig organs into humans - Nature MedicinePigs offer a potentially plentiful supply of organs for humans, but widespread xenotransplantation will require a collaborative and iterative approach to research, as well as involvement of transplant patients and the public.
Baca lebih lajut »
Predicting chronic morbidity in childhood cancer survivors - Nature MedicineNews & Views: Survivors of childhood cancer have high rates of morbidity in later life. LInda Vrooman and Lisa Diller DanaFarber BostonChildrens discuss models to predict severe obesity, which could promote early interventions & better long-term care.
Baca lebih lajut »
A new route to vaccines using PROTACs - Nature BiotechnologyAn influenza vaccine is created by attenuating the live virus through targeted proteolysis NBTNV
Baca lebih lajut »
Precision cancer targeting with antibody pairs - Nature BiotechnologyLogic-gated monoclonal antibodies have been designed to improve safety and efficacy NBTNV
Baca lebih lajut »
Mapping exclusive breastfeeding in Africa between 2000 and 2017 - Nature MedicineThis week is WorldBreastfeedingWeek! Exclusive breastfeeding (EBF) is one of the most effective strategies for preventing ChildMortality. We look back at a fine-scale geospatial analysis of the prevalence of EBF across Africa from 2000–2017.
Baca lebih lajut »